On a roll, Apel­lis adds pos­i­tive PhII C3 da­ta for AMD drug, preps for PhI­II

Just days af­ter grab­bing a $60 mil­lion round to fund a Phase III pro­gram for a ri­val ther­a­py to Alex­ion’s Soliris, Louisville, KY-based Apel­lis is back with a pos­i­tive read­out on its mid-stage tri­al for age-re­lat­ed mac­u­lar de­gen­er­a­tion.

The biotech has been fo­cused on what it be­lieves is a bet­ter way of shut­ting down sev­er­al dis­ease path­ways us­ing a com­ple­ment C3 in­hibitor. In the AMD study, which re­cruit­ed 246 AMD patents with ge­o­graph­ic at­ro­phy at 40 clin­i­cal sites, Apel­lis’ drug APL-2 — de­liv­ered month­ly — pro­duced a 29% av­er­age re­duc­tion in the rate of ge­o­graph­ic at­ro­phy le­sion growth over 12 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER